|
| Study | Design | Patients | Lesions | Tumor volume or size (median) | Type of mets | Dose | Median FU | LC | OS | Toxicity |
|
| Herfarth et al. (2001) [22] | Phase I/II | 33 | 56 | NR by patient | NR by patient (only by lesion) | Dose escalation,
14–26 Gy (1 fx) | 18 mo | 18-mo LC, 67% | 1-yr OS, 72% | No significant
toxicity reported |
|
| Méndez Romero et al., (2006) [23] | Phase I/II (HCC and mets) | 25 (17 liver mets) | 34 | 1.1–322 mL
(22.2 mL) | CRC (14)
Lung (1)
Breast (1)
Carcinoid (1) | 30–37.5 Gy (3 fx) | 12.9 mo | 1-yr LC, 100%
2-yr LC, and 86% | 1-yr OS, 85%,
2-yr OS, 62% | 2 transient grade 3 elevated liver enzymes. |
|
| Hoyer et al. (2006) [24] | Phase II
(CRC oligomets) | 64 (44 liver mets) | NR | 1–8.8 cm
(3.5 cm) | CRC (44) | 45 Gy (3 fx) | 4.3 yr | 2-yr LC, 79%
(by tumor) and 64%
(by patient) | 2-yr OS, 38% | 1 liver failure,
2 severe late GI
toxicities |
|
Rusthoven et al.
(2009) [25] | Phase I/II | 47 | 63 | 0.75–97.98 mL
(14.93 mL) | CRC (15)
Lung (10)
Breast (4)
Ovarian (3)
Esophageal (3)
HCC (2)
Other (10) | Dose escalation,
36–60 Gy (3 fx) | 16 mo | 1-yr LC, 95%
2-yr LC, 92% | Median survival, 20.5 mo,
2-yr OS, 30% | No RILD
1 grade 3 soft tissue toxicity |
|
| Lee et al. (2009) [26] | Phase I/II | 68 | 140 | 1.2–3,090 mL
(75.9 mL) | CRC (40)
Breast (12)
Gallbladder (4)
Lung (2)
Anal canal (2)
Melanoma (2)
Other (6) | Individualized dose,
27.7–60 Gy (6 fx) | 10.8 mo | 1-yr LC, 71% | Median survival, 18 mo | No RILD
10% grade 3/4 acute toxicity,
no grade 3/4 late toxicity |
|
Ambrosino et al.
(2009) [27] | Prospective cohort | 27 | 1–3 lesions for each patient | 20–165 mL
(69 mL) | CRC (11)
Other (16) | 25–60 Gy (3 fx) | 13 mo | Crude LC rate 74% | | No serious toxicity |
|
Rule et al.
(2011) [28] | Phase I | 27 | 37 | NR | | Dose escalation, 30 Gy (3 fx),
50 Gy (3 fx),
60 Gy (5 fx) | 20 mo | 24-mo LC: (30 Gy) 56%; (50 Gy ) 89%; (60 Gy ) 100 | | No serious toxicity |
|
| Scorsetti et al. (2013) [29] | Phase II | 61 | 76 | 1.8–134.3 mL
(18.6 mL) | CRC (29)
Breast (11)
GY (7)
Other (14) | 75 Gy (3 fx) | 12 mo | 12-mo LC 94% | Median survival, 19 mo; 12-mo OS, 83.5%; 18-mo OS, 65% | No RILD |
|
